Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lometrexol

Drug Profile

Lometrexol

Alternative Names: DDATHF; LY 264618; T 904064; T-64

Latest Information Update: 02 Dec 2003

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Amides; Glutamates; Pyrimidines
  • Mechanism of Action DNA synthesis inhibitors; Phosphoribosylglycinamide formyltransferase inhibitors; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 31 Jan 2003 Tularik has terminated its licensing agreement for T 64
  • 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Australia (IV)
  • 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top